TP53 and neoplasm: Unlike Chowdhury and colleagues,30 we neither observed the LOH of chromosome 17 nor an enrichment of wild-type TP53 in patients with chemo-refractory HGSC; rather, every tumor in our cohort harbored a pathogenic TP53 mutation accompanied by loss of the wild-type allele, except for a single case with borderline tumor fraction.